<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765310</url>
  </required_header>
  <id_info>
    <org_study_id>AT002034-1 (7186)</org_study_id>
    <secondary_id>5P01AT002034</secondary_id>
    <nct_id>NCT00765310</nct_id>
  </id_info>
  <brief_title>Lipoic Acid and Prevention of Heart Disease</brief_title>
  <official_title>The Role of R-alpha Lipoic Acid in Prevention of Atherosclerotic Vascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to
      reduce risk factors such as body weight and high blood cholesterol levels in overweight or
      obese participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to
      reduce risk factors such as body weight and high blood cholesterol levels in overweight or
      obese participants.

      Recruitment will be in the Portland, Oregon area.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight and composition</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation and oxidative stress</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Lipoic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo two caps every morning on empty stomach</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>R-alpha lipoic acid</intervention_name>
    <description>600 mg in morning on empty stomach (two 300 mg capsules)</description>
    <arm_group_label>Lipoic Acid</arm_group_label>
    <other_name>Thioctic acid, LA, lipoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>two capsules once daily in morning on empty stomach</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60

          -  Overweight (BMI, 25.0-29.9 kg/m2) or obese (BMI, &gt;30 kg/m2);

          -  Elevated plasma triglycerides (100-400 mg/dl);

          -  Weight stable for the last three months and at lifetime maximum;

          -  Exercise limited to 30 minutes 3 times a week or less;

          -  Hs-CRP level at baseline of ≤ 10 mg/L;

          -  Consuming ≤ 2 alcoholic drinks per day;

        Exclusion criteria:

          -  Pregnant, breastfeeding, or planning to become pregnant before the end of the study.

          -  Having had acute medical conditions, such as hospitalizations or surgeries, at least
             three months prior to entry into the study

          -  Diagnosed as having diabetes (fasting glucose &lt;125 mg/dl for entry), cardiovascular
             disease, congestive heart failure, angina, thyroid disorders, cancer, inflammatory
             disorders or renal, hepatic, or hematological abnormalities;

          -  Currently taking lipid-lowering drugs, anti-hypertensive drugs, insulin , or oral
             hypoglycemic agents, anti-inflammatory drugs, weight loss medications, or hormone
             replacement therapy;

          -  On an extreme diet and not maintaining a prudent diet;

          -  Currently taking vitamin or antioxidant supplements, including R-alpha lipoic acid,
             except standard multivitamin/mineral supplements containing not more than the Daily
             Value (DV) of the vitamins and minerals;

          -  Smoking within the last three months;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Bobe, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Q Purnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon State University</investigator_affiliation>
    <investigator_full_name>Gerd Bobe</investigator_full_name>
    <investigator_title>Principal Investigator, Linus Pauling Institute; Associate Professor, Department of Animal Sciences</investigator_title>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>lipoic acid</keyword>
  <keyword>thioctic acid</keyword>
  <keyword>triglycerides</keyword>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

